ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1122

Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities

Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2021

Keywords: Disparities, Osteoarthritis, patient perspective, Patient reported outcomes, Qualitative Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Osteoarthritis – Clinical Poster III (1118–1134)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Knee osteoarthritis (OA) has worse outcomes in racial/ethnic minorities. Yet, most of the qualitative studies include primarily Caucasian people with knee OA, with minimal or no representation of racial/ethnic minorities. Therefore, our objective was to examine patient perceived solutions to barriers to treatment of knee OA, in a diverse racial/ethnic group of people.

Methods: Nominal groups were conducted with consecutive patients with knee OA at a medical center clinic, oversampling for African Americans with knee OA. Participants discussed potential solutions and rank-ordered their concerns.

Results: Fourteen nominal groups with 48 knee OA patients were conducted with mean age, 60.6 years (standard deviation, 9.8) and knee OA duration, 7.8 years (sd, 5.4); 25% were men, and 46% were African American. The most frequently cited highly-ranked solutions were as follows:

1. More Research, New medications/treatments that are more effective and/or safer, and Restoration of the joint cartilage: Eight of the 14 groups listed this among their top concerns, and nine groups ranked this concern. It received 15% of all votes (43/288).

2. Early diagnosis: Two of the 14 groups listed this among their top concerns, and four groups ranked this concern. It received 7% of all votes (20/288). at an earlier stage.

3. Better and more effective Communication: Five of the 14 groups listed this among their top concerns, and five ranked this concern. It received 10% of all votes (29/288).

4. Public and in-clinic patient Education: Four of the 14 groups listed this among their top concerns, and five ranked this concern. It received 8% of all votes (22/288).

5. Motivation/behavioral modification: Four of the 14 groups listed this among their top concerns, and nine ranked this concern. It received 9% of all votes (26/288).

6. Team Approach: One of the 14 groups listed this among their top concerns, and four ranked this concern. It received 1% of all votes (2/288).

7. Personalized medicine: Six of the 14 groups listed this among their top concerns, and ten ranked this concern. It received 8% of all votes (24/288).

8. Cheaper and more affordable medications and treatments: Three of the 14 groups listed this among their top concerns, and four ranked this concern. It received 5% of all votes (15/288).

Conclusion: A diverse group of participants with knee osteoarthritis, including racial/ethnic minorities, identified several solutions to barriers to the effectiveness of current knee OA treatments. These solutions provide new knowledge. These solutions can also lead to the development of future interventions to improve the outcomes of people with knee OA.


Disclosures: J. Singh, Crealta/Horizon, 2, Medisys, 2, Fidia, 2, PK Med, 2, Two labs Inc, 2, Adept Field Solutions, 2, Clinical Care options, 2, Clearview healthcare partners, 2, Putnam associates, 2, Focus forward, 2, Navigant consulting, 2, Spherix, 2, MedIQ, 2, Jupiter Life Science, 2, UBM LLC, 2, Trio Health, 2, Medscape, 2, WebMD, 2, Practice Point communications, 2, the National Institutes of Health, 2, the American College of Rheumatology, 2, TPT Global Tech, 11, Vaxart pharmaceuticals, 11, Charlotte’s Web Holdings, Inc., 11, Amarin pharmaceuticals, 11, Viking pharmaceuticals, 11, Moderna pharmaceuticals, 11, speaker’s bureau of Simply Speaking, 6, member of the executive of Outcomes Measures in Rheumatology, 4.

To cite this abstract in AMA style:

Singh J. Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/patient-perceived-solutions-to-the-treatment-barriers-in-knee-osteoarthritis-a-qualitative-study-from-a-diverse-patient-group-including-racial-ethnic-minorities/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perceived-solutions-to-the-treatment-barriers-in-knee-osteoarthritis-a-qualitative-study-from-a-diverse-patient-group-including-racial-ethnic-minorities/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology